Loading...
Loading...
ZVSA| Name | Value |
|---|---|
| Revenues | 0.0B |
| Cost of Revenue | 0.0B |
| Gross Profit | 0.0B |
| Operating Expense | 20.8B |
| Operating I/L | -20.8B |
| Other Income/Expense | 1.8B |
| Interest Income | 0.0B |
| Pretax | -19.0B |
| Income Tax Expense | 0.9B |
| Net Income/Loss | -19.8B |
ZyVersa Therapeutics, Inc. is a clinical stage biopharmaceutical company specializing in the development and commercialization of products for the treatment of renal and inflammatory diseases. The company's primary focus is on VAR 200, a cholesterol efflux mediator designed to address focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease, as well as IC 100, a novel inflammasome ASC inhibitor targeting a range of inflammatory diseases.
